- Home
- ACAD vs GBTG Comparison
ACAD vs GBTG Comparison
Compare ACAD & GBTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACAD | GBTG |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.3B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACAD | GBTG |
|---|---|---|
| Price | $25.98 | $7.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | ★ $29.24 | $10.25 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.53 | N/A |
| EPS | ★ 1.54 | 0.01 |
| Revenue | $1,047,118,000.00 | ★ $2,517,000,000.00 |
| Revenue This Year | $15.16 | $14.24 |
| Revenue Next Year | $11.42 | $19.87 |
| P/E Ratio | ★ $16.79 | $418.30 |
| Revenue Growth | ★ 12.69 | 5.71 |
| 52 Week Low | $13.40 | $5.78 |
| 52 Week High | $26.65 | $9.59 |
Technical Indicators
Market Signals| Indicator | ACAD | GBTG |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 58.91 |
| Support Level | $22.81 | $6.81 |
| Resistance Level | $25.20 | $7.89 |
| Average True Range (ATR) | 0.83 | 0.25 |
| MACD | 0.20 | 0.10 |
| Stochastic Oscillator | 95.17 | 91.63 |
Price Performance
Historical ComparisonAbout ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About GBTG Global Business Travel Group Inc.
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.